TI方案治疗晚期非小细胞肺癌的临床观察

Treatment of advanced non-small cell lung cancer with IP regimen

目的 评估紫杉醇 (paclitaxel,TAX)与异环磷酰胺 (ifosfomide ,IFO)组成的TI方案治疗晚期非小细胞肺癌 (NSCLC)的疗效和毒性反应。方法 17例Ⅲ～Ⅳ期NSCLC患者 ,均经病理组织学和(或 )细胞学确诊。治疗剂量 :TAX 135～ 15 0mg/m2 ,静滴第 1天 ;IFO 1.2g/m2 ,静滴第 1～ 5天 ,2 1或2 8d为 1个周期 ,2～ 3个周期为 1疗程。结果 17例患者中 ,CR 1例 ,PR 7例 ,有效率 4 7.1% (8/17)。其中鳞癌和腺癌有效率分别为 5 0 .0 % (4 /8)和 4 2 .9% (4 /7) ,临床疗效差异无显著性 (P >0 .0 5 )。中位缓解期 9.1个月 ,中位生存期 10 .8个月 ,1年生存率 4 7.1% (8/17)。最明显的毒副反应为骨髓抑制、肌肉关节疼痛、脱发等。结论 TI方案治疗晚期非小细胞肺癌有效率较高 ,生存期较长 ,可作为一线治疗方案 。

Objective To evaluate the ef ficacy and side effects of paclitaxel and ifosfomide regimen in treating advanced non-small cell lung cancer (NSCLC ).Methods Seventeen patients with advanced N SCLC diagnosed by pathology or cytology were enrolled into the study.The patients received TAX 135～150 mg/m2 ivgtt on d 1 and IFO 1 .2 g/m2 ivgtt on d1-5 of 21-day or 28-day cycle.The efficacy and side e ffects were evaluat ed after two to three cycles were completed.Resultss Complete remission (CR) was observed in 1 cases, PR in 7 cases.The total response rate was 47.1%.The main s ide effects were neutropenia,gastrointestinal tract reaction.C onclusion The com bined regimen of TAX and IFO for treating advanced NSCLC gives a high response r at e and tolerable side effects.It can be used as the first-line regimen for trea ting advanced NSCLC.